Q1 2026 net income rose 89.5% YoY to KRW 1,203.6B, with strong CSM growth and a 210% K-ICS ratio. Health products now make up 60% of the portfolio, and the company remains committed to stable DPS growth and disciplined capital allocation.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.